There was an interesting article in BioPharma Reporter on the barriers to the biosimilar market in the U.S. What stood out for us in the article is the discussion from GlobalData analyst Lakshmi Dharmajan on alternative delivery systems enabling manufacturers of biosimilars to gain patient preference.

Topical delivery of proteins and peptides is gaining ground and Tergus is helping to lead the charge with formulation and testing of topical biologics.